NCT03113487View on ClinicalTrials.gov

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

August 26, 2022

Study Completion Date

May 4, 2026

Conditions
Recurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Modified Vaccinia Virus Ankara Vaccine Expressing p53

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER